Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals.The drug ...

Benzamil (the benzyl derivative of the epithelial sodium channel blocker amiloride, a commonly used diuretic agent) showed a marked anticorrelation with psoriasis, which implicated down-regulation ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

Sodium channel blockers work by blocking sodium from entering the heart cells. Sodium is one of the electrically charged particles that flows into the cell when a heartbeat occurs. Blocking sodium ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Despite the fact that phenytoin has been used successfully in the past to treat positive symptoms in patients with MS, the investigators at Yale ...